TNFRSF17 and neoplasm: FT576 integrates a BCMA-targeting CAR with an engineered high-affinity, non-cleavable CD16 (hnCD16) receptor, enabling dual functionality: direct CAR-mediated recognition of BCMA-positive tumor cells and antibody-dependent cellular cytotoxicity (ADCC) in combination with therapeutic monoclonal antibodies.